Latest News and Press Releases

— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI...

北京, Dec. 16, 2025 (GLOBE NEWSWIRE) -- BOSS直聘 (Nasdaq: BZ; HKEX: 2076) 今日公告顯示，公司繼續推進股份回購計劃，耗資逾3,500萬元人民幣回購約50萬股普通股。BOSS直聘持續回饋股東，於今年10月完成約8,000萬美元的年度分紅。根據現有回購計劃，截止2026年8月底，BOSS直聘可回購最多為2.5億美元的股份。...

MELBOURNE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Geely Auto anunció oficialmente que su modelo híbrido enchufable global, el Geely STARRAY EM-i (también conocido como Geely EX5 EM-i en...

SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an...

MELBOURNE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Geely Auto officially announced that its global plug-in hybrid model, the Geely STARRAY EM-i (also known as Geely EX5 EM-i in some markets),...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.

SHENZHEN, CHINA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of...

In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%.

BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Mr. Phil Yu...

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.